The technology already has clinical and regulatory validation through two FDA-approved Ascendis products. Skytrofa, a drug for pediatric growth hormone deficiency, won its FDA nod in 2021.

YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 - TransCon CNP NDA submission for achondroplasia planned for Q1 2025 ...

Ascendis Pharma president and CEO Jan Mikkelsen said: “The sBLA submission for TransCon hGH for adult GHD supports our ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

Ascendis Pharma A/S (NASDAQ:ASND) is a commercial stage biotechnology company whose drugs target hormonal disorders and cancer. Its commercially available drug is Skytrofa, and it is used to treat ...

Ascendis claims its drug delivery technology can be tailored to reduce dosing frequency or deliver a therapeutic molecule ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

In October, the company submitted a supplemental biologics licence application (sBLA) for TransCon hGH, marketed as Skytrofa, to treat growth hormone deficiency. Ascendis stock saw a slight uptick ...

The firm continues to like the Ascendis story heading into the U.S ... However, it trimmed its Q4 and Q4 Skytrofa revenue estimates and now models total 2024 Skytrofa revenue of EUR 215M.

In the third quarter, Ascendis Pharma's growth hormone therapy Skytrofa is projected to possibly fall short of consensus revenue estimates of €61 million, with the firm's own forecast being € ...

The company lowered its full-year sales guidance for Skytrofa. Ascendis also secured a $150 million funding deal with Royalty Pharma based on U.S. sales of Yorvipath.

The discount rate applied to these earnings remains unchanged at 10%. In the third quarter, Ascendis Pharma's growth hormone therapy Skytrofa is projected to possibly fall short of consensus revenue ...